Ceribell (CBLL) Gains from Investment Securities (2023 - 2024)

Ceribell (CBLL) posted Gains from Investment Securities of $1.1 million for Q4 2024, up 523.7% on a QoQ basis from $173000.0 in Q3 2024.

Ceribell (CBLL) Gains from Investment Securities (2023 - 2024) Analysis & Trends

Ceribell's Gains from Investment Securities history runs 2 years deep, the most recent figure standing at $1.1 million for Q4 2024.

Quarterly Gains from Investment Securities changed N/A year-over-year to $1.1 million in Q4 2024, while the trailing twelve-month figure through Dec 2025 was $1.3 million (down 16.31% YoY) and the FY2024 annual result came in at $1.5 million, up 3216.67% from the prior year.
Gains from Investment Securities was $1.1 million for Q4 2024 at Ceribell, up from $173000.0 in the prior quarter.
Across five years, Gains from Investment Securities topped out at $1.1 million in Q4 2024 and bottomed at $2000.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	183.73 Bn	176.43 Bn	6.27 Bn
2	Stryker	128.82 Bn	125.94 Bn	3.81 Bn
3	Medtronic	108.74 Bn	99.52 Bn	6.41 Bn
4	Boston Scientific	68.40 Bn	66.95 Bn	3.61 Bn
5	Edwards Lifesciences	47.42 Bn	43.74 Bn	1.29 Bn
6	GE HealthCare Technologies	28.47 Bn	26.18 Bn	1.98 Bn
7	Dexcom	28.42 Bn	27.30 Bn	750.30 Mn
8	Smith & Nephew	26.97 Bn	26.40 Bn	-
9	Koninklijke Philips	25.52 Bn	22.39 Bn	2.07 Bn
10	Ceribell	659.48 Mn	518.30 Mn	23.12 Mn

Download Data